[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336932-105":59,"doc-detail-336932-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-microenvironment-on-a-chip-the-construction-and-application","Tumor-microenvironment-on-a-chip - the construction and application","","Cancer remains a major threat to human life despite substantial time and money devoted to treatment. Low efficacy is driven in part by cancer heterogeneity, with unclear molecular mechanisms of tumorigenesis and the added complexity of human physiology. Animal models also struggle to replicate the human tumor microenvironment, limiting progress in novel cancer therapies. Tumor-microenvironment-on-chip (TMOC) combines three-dimensional cell culture with microfluidic systems to model key in vivo tumor components dynamically. This review summarizes TMOC advancements, TMOC types, and applications across cancers, and argues that stronger integration with tissue engineering and microphysiological environments is needed to refine TMOC as a preclinical model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-microenvironment-on-a-chip-the-construction-and-application/336932/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-microenvironment-on-a-chip-the-construction-and-application/336932.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cancer treatment efficacy often low?","Question",{"text":112,"@type":113},"Cancer heterogeneity contributes to poor efficacy. The molecular mechanisms behind tumorigenesis remain unclear, and human physiology is complex.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is Tumor-microenvironment-on-chip (TMOC)?",{"text":117,"@type":113},"TMOC is a research platform that integrates three-dimensional cell culture with microfluidic systems. It simulates essential components of the in vivo tumor microenvironment in a dynamic chip setting.",{"name":119,"@type":110,"acceptedAnswer":120},"How does TMOC aim to improve cancer research compared with traditional models?",{"text":121,"@type":113},"TMOC addresses shortcomings of animal models that cannot accurately replicate the human tumor microenvironment. It also seeks to enhance preclinical relevance beyond conventional 2D cell models by better representing tumor microenvironment features.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336932,1790874328,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Xu etal. Cell Communication and Signaling (2024) 22:515  \n[https://doi.org/10.1186/s12964-024-01884-4](https://doi.org/10.1186/s12964-024-01884-4)  \nCell Communication and Signaling  \n REVIEW Open Access  \nTumor-microenvironment-on-a-chip: the construction and application  \nHanzheng Xu1,2†, Jiangtao Wen3†, Jiahua Yang1†, Shufen Zhou1,2, Yijie Li 1, Ke Xu4,5*, Wei Li 1* and Sen Li 1*  \nAbstract  \nCurrently, despite the vast amounts of time and money invested in cancer treatment, cancer remains one of the primary threats to human life. The primary factor contributing to the low treatment efficacy is cancer heterogeneity. The unclear molecular mechanisms underlying tumorigenesis, coupled with the complexity of human physiology, and the inability of animal models to accurately replicate the human tumor microenvironment, pose significant hurdles in the development of novel cancer therapies. Tumor-microenvironment-on-chip (TMOC) represents a research platform that integrates three-dimensional cell culture with microfluidic systems, simulating the essential components and physiological traits ofthe in vivo tumor microenvironment. It offers a dynamic setting within the chip system to study tumor progression, potentially heralding a breakthrough in cancer research. In this review, we will summarize the current advancements in this platform, encompassing various types ofTMOCs and their applications in different types of cancer. From our perspective, the TMOC platform necessitates enhanced integration with tissue engineering techniques and microphysiological environments before it can evolve into a more refined preclinical model for cancer research.  \nKeywords Tumor microenvironment, Microfluidics, Tumor chip, Cancer modeling, In vitro models  \n†Hanzheng Xu, Jiangtao Wen and Jiahua Yang contributed equally to this work.  \n*Correspondence: Ke Xu  \n[kexu@shu.edu.cn](kexu@shu.edu.cn); [cola519@163.com](cola519@163.com)  \nWei Li[liwei1511972@163.com](liwei1511972@163.com)[ ](liwei1511972@163.com)Sen Li [lee_lisen@163.com](lee_lisen@163.com)  \n1 Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China  \n2 State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China  \n3 Linfen People’s Hospital, The Seventh Clinical School of Shanxi Medical University, Shanxi 041000, China  \n4 Institute of Translational Medicine, Shanghai University, Shanghai 200444, China  \n5 Wenzhou Institute of Shanghai University, Wenzhou 325000, China  \nIntroduction  \nAccording to the latest report from the World Health Organization (WHO), cancer accounts for one-sixth of global deaths, and global cancer cases will increase by 60% by 2040, reaching approximately 81% in developing countries [1]. The high mortality rate of cancer indicates that it seriously threatens human life and health, so it is urgent to develop more effective therapeutic drugs [2]. In fact, in the process of clinical oncology research, only about 5% of anti-cancer drugs enter phase I clinical trials and are finally approved by the FDA [3], and more than 80% of drug candidates stopped at the development stage [4]. Clinical screening has extremely low success rates. Moreover, the total cost of a drug entering the market is estimated to be around billions of dollars, and the market risks are extremely high.  \nThe low success rate of anticancer drugs entering clinical trials demonstrates certain predictive shortcomings of current preclinical models for disease and drug screening  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a l","cbCaiecZJR75KwiH","https://ap.wps.com/l/cbCaiecZJR75KwiH","pdf",6803421,22,"English","# Abstract\n# Introduction\n## Global burden and limits of current drug development\n## Preclinical models for anticancer drug screening\n# Open Access license information","[{\"question\":\"Why is cancer treatment efficacy often low?\",\"answer\":\"Cancer heterogeneity contributes to poor efficacy. The molecular mechanisms behind tumorigenesis remain unclear, and human physiology is complex.\"},{\"question\":\"What is Tumor-microenvironment-on-chip (TMOC)?\",\"answer\":\"TMOC is a research platform that integrates three-dimensional cell culture with microfluidic systems. It simulates essential components of the in vivo tumor microenvironment in a dynamic chip setting.\"},{\"question\":\"How does TMOC aim to improve cancer research compared with traditional models?\",\"answer\":\"TMOC addresses shortcomings of animal models that cannot accurately replicate the human tumor microenvironment. It also seeks to enhance preclinical relevance beyond conventional 2D cell models by better representing tumor microenvironment features.\"}]","Tumor-microenvironment-on-a-chip - the construction and application | PDF",1790017118,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a719533091dcf99fb5e19d9919c5e82.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e06e7a30fc3bac08e5487a3b91258a0.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae172b87fa0ad85710f0b7ac0f988083.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c9d420a2dd58c3191b9eb54f1710a60.webp",980,1301]